The compensatory enrichment of sphingosine -1- phosphate harbored on glycated high-density lipoprotein restores endothelial protective function in type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Tong, Xunliang ^a   Lv, Pu ^a   Mathew, Anna V ^c   Liu, Donghui ^d   Niu, Chenguang ^b,e   Wang, Yan ^d   Ji, Liang ^b,e   Li, Jizhao ^b,e   Fu, Zhiwei ^b,e   Pan, Bing ^b,e   Pennathur, Subramaniam ^c   Zheng, Lemin ^b,e   Huang, Yining ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c UNIVERSITY OF MICHIGAN   (United States)

^d ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Cyclooxygenase 2; Endothelial cells; High density lipoprotein; Sphingosine 1 phosphate; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; HIGH DENSITY LIPOPROTEIN; LYASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPID; PROSTACYCLIN; RECEPTOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 3 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLYCATION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION;

CELLS, CULTURED; CYTOPROTECTION; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; SPHINGOSINE;

EID: 84899942750     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-82     Document Type: Article

References (37)

1. Strojek K. Features of macrovascular complications in type 2 diabetic patients. Acta Diabetol 2003, 40(Suppl 2):S334-S337.
2. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications 2002, 16(6):401-415. 10.1016/S1056-8727(02)00202-7, 12477625.
3. Neeli H, Gadi R, Rader DJ. Managing diabetic dyslipidemia: beyond statin therapy. Curr Diab Rep 2009, 9(1):11-17. 10.1007/s11892-009-0004-y, 19192419.
4. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012, 8(4):237-245. 10.1038/nrendo.2011.235, 22271188.
5. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357(13):1301-1310. 10.1056/NEJMoa064278, 17898099.
6. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009, 5(3):150-159. 10.1038/ncpendmet1066, 19229235.
7. Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 2008, 118(2):161-180. 10.1016/j.pharmthera.2008.01.002, 18420277.
8. Karaoglu A, Tunc T, Aydemir G, Onguru O, Uysal B, Kul M, Aydinoz S, Oztas E, Sarici U. Role of cyclooxygenase 2 and endothelial nitric oxide synthetase in preclinical atherosclerosis. Fetal Pediatr Pathol 2012, 31(6):432-438. 10.3109/15513815.2012.659408, 22443285.
9. Damirin A, Tomura H, Komachi M, Tobo M, Sato K, Mogi C, Nochi H, Tamoto K, Okajima F. Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/prostaglandin I2 pathway in human coronary artery smooth muscle cells. Mol Pharmacol 2005, 67(4):1177-1185. 10.1124/mol.104.004317, 15625281.
10. Rodriguez C, Gonzalez-Diez M, Badimon L, Martinez-Gonzalez J. Sphingosine-1-phosphate: a bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 2009, 101(4):665-673.
11. Argraves KM, Argraves WS. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 2007, 48(11):2325-2333. 10.1194/jlr.R700011-JLR200, 17698855.
12. Bourquin F, Capitani G, Grutter MG. PLP-dependent enzymes as entry and exit gates of sphingolipid metabolism. Protein Sci 2011, 20(9):1492-1508. 10.1002/pro.679, 3190145, 21710479.
13. Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, Yamashita T, Proia RL. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 2004, 279(28):29367-29373. 10.1074/jbc.M403937200, 15138255.
14. Aguilar A, Saba JD. Truth and consequences of sphingosine-1-phosphate lyase. Adv Biol Regul 2012, 52(1):17-30. 10.1016/j.advenzreg.2011.09.015, 3560305, 21946005.
15. Serra M, Saba JD. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul 2010, 50(1):349-362. 10.1016/j.advenzreg.2009.10.024, 2862839, 19914275.
16. Matsuki K, Tamasawa N, Yamashita M, Tanabe J, Murakami H, Matsui J, Imaizumi T, Satoh K, Suda T. Metformin restores impaired HDL-mediated cholesterol efflux due to glycation. Atherosclerosis 2009, 206(2):434-438. 10.1016/j.atherosclerosis.2009.03.003, 19376519.
17. Nobecourt E, Zeng J, Davies MJ, Brown BE, Yadav S, Barter PJ, Rye KA. Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. Diabetologia 2008, 51(6):1008-1017. 10.1007/s00125-008-0986-z, 18437350.
18. Liu D, Ji L, Zhang D, Tong X, Pan B, Liu P, Zhang Y, Huang Y, Su J, Willard B, Zheng L. Nonenzymatic glycation of high-density lipoprotein impairs its anti-inflammatory effects in innate immunity. Diabetes Metab Res Rev 2012, 28(2):186-195. 10.1002/dmrr.1297, 21928330.
19. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004, 114(4):529-541. 10.1172/JCI200421109, 503769, 15314690.
20. Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, Smith JD, Kinter M. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 2005, 280(1):38-47.
21. Pan B, Ma Y, Ren H, He Y, Wang Y, Lv X, Liu D, Ji L, Yu B, Wang Y, Chen YE, Pennathur S, Smith JD, Liu G, Zheng L. Diabetic HDL is dysfunctional in stimulating endothelial cell migration and proliferation due to down regulation of SR-BI expression. PLoS One 2012, 7(11):e48530. 10.1371/journal.pone.0048530, 3487724, 23133640.
22. Baranowski M, Blachnio-Zabielska A, Hirnle T, Harasiuk D, Matlak K, Knapp M, Zabielski P, Gorski J. Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide. J Lipid Res 2010, 51(1):74-80. 10.1194/jlr.M900002-JLR200, 2789788, 19617631.
23. Saba JD, Hla T. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res 2004, 94(6):724-734. 10.1161/01.RES.0000122383.60368.24, 15059942.
24. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008, 9(2):139-150. 10.1038/nrm2329, 18216770.
25. Tong X, Peng H, Liu D, Ji L, Niu C, Ren J, Pan B, Hu J, Zheng L, Huang Y. High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate. Cardiovasc Diabetol 2013, 12(1):27. 10.1186/1475-2840-12-27, 3599898, 23360427.
26. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52(11):2745-2756. 10.1172/JCI107470, 302542, 4355998.
27. Chung BH, Wilkinson T, Geer JC, Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res 1980, 21(3):284-291.
28. Cham BE, Knowles BR. A solvent system for delipidation of plasma or serum without protein precipitation. J Lipid Res 1976, 17(2):176-181.
29. Lee MH, Hammad SM, Semler AJ, Luttrell LM, Lopes-Virella MF, Klein RL. HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate. J Lipid Res 2010, 51(9):2619-2628. 10.1194/jlr.M003988, 2918445, 20522601.
30. Liu D, Ji L, Tong X, Pan B, Han JY, Huang Y, Chen YE, Pennathur S, Zhang Y, Zheng L. Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1. Am J Physiol Cell Physiol 2011, 301(3):739-748.
31. Burnette WN. Western blotting: electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981, 112(2):195-203. 10.1016/0003-2697(81)90281-5, 6266278.
32. Read JT, Cheng H, Hendy SC, Nelson CC, Rennie PS. Receptor-DNA interactions: EMSA and footprinting. Methods Mol Biol 2009, 505:97-122. 10.1007/978-1-60327-575-0_6, 19117141.
33. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005, 31(5):429-439. 10.1016/S1262-3636(07)70213-6, 16357786.
34. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011, 11(6):403-415. 10.1038/nri2974, 3368251, 21546914.
35. Kontush A, Therond P, Zerrad A, Couturier M, Negre-Salvayre A, de Souza JA, Chantepie S, Chapman MJ. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007, 27(8):1843-1849. 10.1161/ATVBAHA.107.145672, 17569880.
36. Keul P, Lucke S, von Wnuck LK, Bode C, Graler M, Heusch G, Levkau B. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 2011, 108(3):314-323. 10.1161/CIRCRESAHA.110.235028, 21164103.
37. Whetzel AM, Bolick DT, Srinivasan S, Macdonald TL, Morris MA, Ley K, Hedrick CC. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res 2006, 99(7):731-739. 10.1161/01.RES.0000244088.33375.52, 16960101.